One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus

Clinical Immunology

Volumn 160, Issue 2, 2015, Pages 155-162

  van Asseldonk, Edwin J P ^a   van Poppel, Pleun C M ^a   Ballak, Dov B ^a   Stienstra, Rinke ^a,b   Netea, Mihai G ^a   Tack, Cees J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Adipose tissue; Anakinra; Inflammation; Insulin sensitivity; Interleukin 1; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN TISSUE; INFLAMMATION; INJECTION PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OBESITY; PRIORITY JOURNAL; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 1; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; BLOOD GLUCOSE; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; OBESITY; OVERWEIGHT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84938085085     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.06.003     Document Type: Article

References (30)

1. Bunout D., Munoz C., Lopez M., de la Maza M.P., Schlesinger L., Hirsch S., et al. Interleukin 1 and tumor necrosis factor in obese alcoholics compared with normal-weight patients. Am. J. Clin. Nutr. 1996, 63(3):373-376.
2. Manica-Cattani M.F., Bittencourt L., Rocha M.I., Algarve T.D., Bodanese L.C., Rech R., et al. Association between interleukin-1 beta polymorphism (+3953) and obesity. Mol.Cell Endocrinol. 2010, 314(1):84-89.
3. Stienstra R., Joosten L.A., Koenen T., van Tits B., van Diepen J.A., van den Berg S.A., et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2010, 12(6):593-605.
4. Tack C.J., Stienstra R., Joosten L.A., Netea M.G. Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family. Immunol. Rev. 2012, 249(1):239-252.
5. Koenen T.B., Stienstra R., van Tits L.J., Joosten L.A., van Velzen J.F., Hijmans A., et al. The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue. Endocrinology 2011, 152(10):3769-3778.
6. Dasu M.R., Devaraj S., Zhao L., Hwang D.H., Jialal I. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 2008, 57(11):3090-3098.
7. Youssef-Elabd E.M., McGee K.C., Tripathi G., Aldaghri N., Abdalla M.S., Sharada H.M., et al. Acute and chronic saturated fatty acid treatment as a key instigator of the TLR-mediated inflammatory response in human adipose tissue, in vitro. J. Nutr. Biochem. 2012, 23(1):39-50.
8. Maedler K., Sergeev P., Ris F., Oberholzer J., Joller-Jemelka H.I., Spinas G.A., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 2002, 110(6):851-860.
9. Yki-Jarvinen H., Helve E., Koivisto V.A. Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes 1987, 36(8):892-896.
10. Pouwels M.J., Tack C.J., Hermus A.R., Lutterman J.A. Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant Type 2 diabetic patients. DiabetMed 2003, 20(1):76-79.
11. Mandrup-Poulsen T., Zumsteg U., Reimers J., Pociot F., Morch L., Helqvist S., et al. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine 1993, 5(3):185-191.
12. Poitout V., Robertson R.P. Glucolipotoxicity: fuel excess and beta-cell dysfunction. EndocrRev 2008, 29(3):351-366.
13. Cnop M. Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes. BiochemSocTrans 2008, 36(Pt 3):348-352.
14. Leahy J.L., Cooper H.E., Deal D.A., Weir G.C. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions. J. Clin. Invest. 1986, 77(3):908-915.
15. Larsen C.M., Faulenbach M., Vaag A., Volund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. NEnglJMed 2007, 356(15):1517-1526.
16. Owyang A.M., Maedler K., Gross L., Yin J., Esposito L., Shu L., et al. XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology 2010, 151(6):2515-2527.
17. Ridker P.M., Howard C.P., Walter V., Everett B., Libby P., Hensen J., et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012, 126(23):2739-2748.
18. Rissanen A., Howard C.P., Botha J., Thuren T. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes. Metab. 2012, 14(12):1088-1096.
19. Cavelti-Weder C., Babians-Brunner A., Keller C., Stahel M.A., Kurz-Levin M., Zayed H., et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012, 35(8):1654-1662.
20. Abbink E.J., De Graaf J., De Haan J.H., Heerschap A., Stalenhoef A.F., Tack C.J. Effects of pioglitazone in familial combined hyperlipidaemia. J. Intern. Med. 2006, 259(1):107-116.
21. Stienstra R., Saudale F., Duval C., Keshtkar S., Groener J.E., van Rooijen N., et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010, 51(2):511-522.
22. Schalkwijk C.G., Poland D.C., van Dijk W., Kok A., Emeis J.J., Drager A.M., et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999, 42(3):351-357.
23. Jansen H.J., van Essen P., Koenen T., Joosten L.A., Netea M.G., Tack C.J., et al. Autophagy activity is up-regulated in adipose tissue of obese individuals and modulates proinflammatory cytokine expression. Endocrinology 2012, 153(12):5866-5874.
24. van Asseldonk E.J., Stienstra R., Koenen T.B., Joosten L.A., Netea M.G., Tack C.J. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2011, 96(7):2119-2126.
25. Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998, 41(12):2196-2204.
26. Nagareddy P.R., Kraakman M., Masters S.L., Stirzaker R.A., Gorman D.J., Grant R.W., et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab. 2014, 19(5):821-835.
27. Koenen T.B., Stienstra R., van Tits L.J., de Graaf J., Stalenhoef A.F., Joosten L.A., et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue. Diabetes 2011, 60(2):517-524.
28. Donath M.Y., Storling J., Berchtold L.A., Billestrup N., Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. EndocrRev 2008, 29(3):334-350.
29. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. NatImmunol 2010, 11(2):136-140.
30. Pham M.N., Hawa M.I., Pfleger C., Roden M., Schernthaner G., Pozzilli P., et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia 2011, 54(7):1630-1638.